Clearside Biomedical, Inc.
clearsidebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 14, 2025. Its latest SEC filing is a 15-12G from Jan 7, 2026.
10-Q for Q3 FY2025, filed Nov 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops small-molecule eye therapies and an injection device for delivering drugs to the back of the eye, and licenses the platform to companies developing eye treatments.
10-K for FY2024, filed Mar 27, 2025We are a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal…View ↗
We are leveraging our SCS injection platform by building an internal research and development pipeline targeting retinal diseases and by…View ↗
We have research capabilities focused on developing proprietary therapeutic formulations to utilize with our SCS Microinjector. Our current…View ↗
How Did They Make Money?
Licensees pay upfront fees, milestone payments and royalties on future product sales, and may also pay for SCS Microinjector devices and support; payment timing follows each contract’s billing schedule.
10-K for FY2024, filed Mar 27, 2025The Company recognizes revenue from its contracts with customers under Financial Accounting Standards Board Accounting Standards…View ↗
The Company receives payments from its customers based on billing schedules established in each contract. Up-front and other payments may…View ↗
We have not generated any revenue from the sale of XIPERE and we do not expect to generate any other product revenue unless or until we…View ↗
-
10-K for FY2024, filed Mar 27, 2025
FY2024 revenue by product or service ↗
$1.7M
-
10-K for FY2024, filed Mar 27, 2025
$1.7M ↗
| Segment | Share | Revenue |
|---|---|---|
|
License
|
102%
FY2021: 100%
|
License, FY2024
$1.7M Sources
|
|
Product and Service
|
42% |
Product and Service, FY2024
$700K Sources
|
|
Training Materials and Clinical Trial Products
|
54% |
Training Materials and Clinical Trial Products, FY2024
$900K Sources
|
Who Were Their Customers?
Other companies developing ophthalmic therapies work with Clearside through license and collaboration agreements for the SCS technology; Bausch + Lomb launched XIPERE in the United States.
10-K for FY2024, filed Mar 27, 2025We are leveraging our SCS injection platform by building an internal research and development pipeline targeting retinal diseases and by…View ↗
We have not generated any revenue from the sale of XIPERE and we do not expect to generate any other product revenue unless or until we…View ↗
Our SCS Microinjector has been used in thousands of suprachoroidal injections in our clinical trials and the clinical trials of our…View ↗
Did Revenues Turn Into Profits?
No. It lost $34.4M in FY2024.
10-K for FY2024, filed Mar 27, 2025
−$28.9MView ↗
10-K for FY2024, filed Mar 27, 2025
−$34.4MView ↗
10-K for FY2024, filed Mar 27, 2025
−$25.7MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 14, 2025
−$6MView ↗
- ▼ −22% (Loss)
- vs −$7.7M in Q3 FY2024
-
Dec 29, 2025
Court approves bidding rules for proposed asset sale
Health Ocean was designated as the minimum bidder; higher or better offers may compete for substantially all assets.
Sources
8-K, filed Dec 29, 2025
On December 10, 2025, the Company filed a motion (the “Bidding Procedures Motion”) (Docket No. 50) that sought approval of, among other…View ↗
-
Dec 8, 2025
Files to remove its common stock from Nasdaq
Trading was suspended on Nasdaq and the shares began trading on the OTC Pink Limited Market.
Sources
8-K, filed Dec 8, 2025
On December 8, 2025, Clearside Biomedical, Inc. (the “Company”) filed a Form 25 (Notification of Removal of Listing) (the “Company Form…View ↗
-
Nov 25, 2025
Files for Chapter 11 and seeks sale of substantially all assets
The company said it would continue operating under court oversight while seeking a sale to the highest bidder.
Sources
8-K, filed Nov 25, 2025
On November 23, 2025, Clearside Biomedical, Inc. (the “Company”) filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11…View ↗
Shrank. Revenue fell 79% in 4 years, from $7.9M in FY2020 to $1.7M in FY2024, about 32% a year.
Pipeline focus
The older report described gene therapy as a research direction and said the company would seek partners; the latest describes its internal research as focused on small molecules.
10-K for FY2021, filed Mar 11, 2022 10-K for FY2024, filed Mar 27, 2025We have research capabilities focused on developing proprietary therapeutic formulations to utilize with our SCS Microinjector. Our current…View ↗
Who Did They Compete With?
Competes with Bristol-Myers Squibb, Harrow, Allergan, Bausch, Alimera, Oxular, Regeneron, Pfizer, Genentech, Novartis, Ocular Therapeutics, Eyepoint, REGENXBIO, Adverum, 4D Molecular Therapeutics, Everads Therapy, and Uneedle
10-K for FY2024, filed Mar 27, 2025XIPERE faces competition from other commercially available forms of TA and other topical, injectable and implantable corticosteroids…View ↗
Loading...
